Benytte kunstig intelligens for utvikling av nye immunrettede terapier

Offentlig prosjektsammendrag

NEC Oncoimmunity (NOI) aims to provide a comprehensive AI toolbox for target identification and therapy design in oncology, infectious, and autoimmune diseases. In oncology, NOI will launch new platform features to include completely novel antigen classes, analyze large patient cohorts, and incorporate features like immune evasion and host-tumor interactions. For infectious and autoimmune diseases, NOI leverages AI-driven structural biology to link B cell epitopes with biological function, enabling antibody and vaccine target discovery. This integrated approach supports pharmaceutical partners in both target identification and biomolecule design. Wet lab validation will be key to ensuring the tools' relevance for drug development.